225 related articles for article (PubMed ID: 27585978)
1. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
[TBL] [Abstract][Full Text] [Related]
4. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
[TBL] [Abstract][Full Text] [Related]
6. PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT
BioDrugs; 2018 Dec; 32(6):639-642. PubMed ID: 30284704
[TBL] [Abstract][Full Text] [Related]
7. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.
Chow V; Oh M; Gessner MA; Fanjiang G
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783
[TBL] [Abstract][Full Text] [Related]
9. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
10. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
11. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
Farkas K; Molnár T
Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
Park W; Lee SJ; Yun J; Yoo DH
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
[TBL] [Abstract][Full Text] [Related]
15. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
16. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
18. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
Palaparthy R; Rehman MI; von Richter O; Yin D
Expert Opin Biol Ther; 2019 Oct; 19(10):1065-1074. PubMed ID: 31284794
[No Abstract] [Full Text] [Related]
20. Physicochemical characterization of Remsima.
Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]